Galactomannan Testing During Mold-Active Prophylaxis

Oliver A. Cornely

Department I of Internal Medicine, Clinical Trials Centre Cologne, Center for Integrated Oncology Köln Bonn, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, German Centre for Infection Research, University of Cologne, Germany

(See the Major Article by Duarte et al on pages 1696–702.)

Keywords. galactomannan; prophylaxis; leukemia; bronchoalveolar lavage.

Choosing a prophylactic approach is a strategic decision impacting the choice, timing, and even the indication of in vitro diagnostic tests and antifungal treatments. In the past, clinical studies informing clinical decisions were conducted in settings without prophylaxis. One may object, that empiric antifungal treatment trials allowed enrolling patients on antifungal prophylaxis with fluconazole and itraconazole. However, prophylaxis with these older azoles cannot be considered effective in preventing mold infection in pivotal protocols [1–3].

There is a debate on how to treat patients with breakthrough infections during posaconazole or voriconazole prophylaxis. To date, no convincing trial addresses this clinically challenging question, likely because of the very low breakthrough rates observed [4–6]. Today’s diagnostic gold standard still depends on tissue sampling, a principle unchanged since the 19th century [7, 8].

In this issue of Clinical Infectious Diseases, Duarte et al report their experience with posaconazole prophylaxis in hematological populations at high risk. The Catalan Institute of Oncology, Barcelona, is one of the premier cancer centers in Spain and their prospective 4-year study period covers 121 patients and 262 consecutive treatment episodes. The study focuses on the effect of prophylaxis on in vitro diagnostics, namely, serum galactomannan testing in a population on active prophylaxis.

During posaconazole prophylaxis, the rate of positive galactomannan screening tests was low, which is in line with previous observations in animal models and in humans [9, 10]. Interference of the posaconazole molecule with the assay itself appears unlikely, although false-negative serum results have been reported in the past [11]. When posaconazole is used prophylactically, the performance of galactomannan screening tests is impacted by the very low pretest probability of invasive fungal infection (IFI); in other words, successful prophylaxis results in low IFI breakthrough rates. In that setting, one hardly detects a case of aspergillosis by galactomannan testing, but false-positive results become important, as they trigger a diagnostic workup and have the potential to mislead the clinician. It is important to know that we can harm simply by applying in vitro diagnostics, if the false-positive results outnumbert the true positives. Actually, galactomannan screening may not be advisable at all during effective antifungal prophylaxis. Many centers must have observed this, but none published their observation as result of a prospective study. Thanks to the very timely study of Duarte et al, we now have evidence to personalize diagnostics according to the initial strategic decision.

How do Duarte’s findings affect prophylactic strategies? At the University Hospital of Cologne, galactomannan screening 3 times weekly was routine practice when posaconazole prophylaxis was introduced in January 2006 [11, 12]. In 2003–2005, we ran 6950 serum galactomannan assays on samples of 190 patients, or 35 galactomannan tests per patient. When we abandoned galactomannan screening during prophylaxis in 2009, the average number substantially decreased to 8 galactomannan tests per patient (2391 tests in 273 patients) (Cologne Cohort of Neutropenic Patients, NCT01821456).

Should we stop all galactomannan testing? There is at least one caveat: The pretest probability of the galactomannan
test increases, if the test is not used for screening but for confirmation of IFI in symptomatic patients. Persistent fever of unknown etiology should always trigger a chest computed tomographic scan regardless of posaconazole prophylaxis, as any lung infiltrate should prompt bronchoalveolar lavage for microbiological and virological workup [13]. In Cologne we do, for example, test galactomannan on bronchoalveolar lavage fluid, although there is an ongoing debate regarding its diagnostic value [14–16]. Our infectious diseases team further advises that an investigational galactomannan test series be done over 5 consecutive days to confirm the diagnosis of invasive aspergillosis. Therefore, we quite intensely use galactomannan for the purpose of confirming disease, in a situation where the positive predictive value reaches almost 90%.

Importantly, Duarte reminds us that the result of any in vitro diagnostic assay needs to be interpreted in the clinical context. Appreciating all known uncertainties of the galactomannan assay, there are populations where galactomannan screening is considered state of the art [17]. In acute lymphoblastic leukemia, vinca alkaloids are a cornerstone of induction chemotherapy regimens, but mold-active azoles inhibit their metabolism, resulting in neuropathy [18]. Azole prophylaxis is not recommended, and alternative prophylactic regimens are currently undergoing clinical evaluation (eg, in the Ambiguard trial [NCT01259713]).

In general, it becomes apparent that we need more advanced in vitro diagnostic assays. Ideally these would detect not only Aspergillus species, but other unmet clinical needs, for example, in managing mucormycosis [19]. Although we may have to wait for such tests to arrive, what we can tackle immediately is education. Every large hospital treating patients with hematological malignancy should establish multidisciplinary teams focusing on infections in these patients, because management of invasive fungal infection is far too complex to be dealt with by one specialty alone.

**Note**

**Potential conflict of interest.** The author has received grants and personal fees from Astellas, Gilead, Merck MSD, GSK, Optimer, Pfizer, and 3M; grants from Actelion, Quintiles, Bayer, Celgene, Miltenyi, Viropharma, and Genzyme; and personal fees from Da Volterra, Daiichi Sankyo, F2G, and Sanofi Pasteur from outside the submitted work.

The author has submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

**References**

1. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999; 340:764–71.
2. Walsh TJ, Teplinger H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351:1391–402.
3. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346:225–34.
4. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356:348–59.
5. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356:335–47.
6. Anandaraj MR, Grigg A, Downey MT, et al. Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazoleitraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period. Haematologica 2012; 97:459–63.
7. Virchow R. Beiträge zur Lehre von den beim Menschen vorkommenden pflanzlichen Parasiiten. Archiv für pathologische Anatomie 1856; 9:557–93.
8. Paltauf A. Mycosis mucorina. Ein Beitrag zur Kenntnis der menschlichen Fadenpilzerkrankungen. Archív für pathologische Anatomie 1885; 102:543–64.
9. Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillusgalactomannan enzyme immunoassay. Clin Infect Dis 2005; 40:1762–9.
10. Petratiene R, Petraitis V, Groll AH, et al. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia. Antimicrob Agents Chemother 2001; 45:857–69.
11. Vehreschild JJ, Ruping MJ, Wisplinghoff H, et al. Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukemia (AML): a 6 year experience of the Cologne AML cohort. J Antimicrob Chemother 2010; 65:1466–71.
12. Maertens J, Theunissen K, Verhoef G, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005; 41:1242–50.
13. Maertens J, Maertens V, Theunissen K, et al. Bronchoalveolar lavage fluid galactomannan for the diagnosis of invasive pulmonary aspergillosis in patients with hematologic diseases. Clin Infect Dis 2009; 49:1688–93.
14. Donnelly JP, Leelang MM. Galactomannan detection and diagnosis of invasive aspergillosis. Clin Infect Dis 2010; 50:1070–1; author reply 1–2.
15. Affolter K, Tam M, Jahn K, et al. Galactomannan in bronchoalveolar lavage for diagnosing invasive fungal disease. Am J Respir Crit Care Med 2014; 190:309–17.
16. Vehreschild JJ. As galactomannan disappoints, our quest for a feasible diagnostic standard for invasive aspergillosis continues. Am J Respir Crit Care Med 2014; 190:248–9.
17. Ruhnke M, Böhme A, Buchheidt D, et al. Diagnosis of invasive fungal infections in hematology and oncology—guidelines from the Infectious Diseases Working Party in Haematology and Oncology of the German Society for Haematology and Oncology (AGIHO). Ann Oncol 2012; 23:823–33.
18. Eiden C, Palenzuela G, Hillaire-Buys D, et al. Posaconazole-increased vincristine neurotoxicity in a child: a case report. J Pediatr Hematol Oncol 2009; 31:292–5.
19. Cornely OA, Arikan-Akdaglı S, Dannaoui E, et al. ESCMID and ECM open joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect 2014; 20(suppl 3):5–26.